Cocrystal Pharma, Inc. (OTCBB:COCP) Files An 8-K Regulation FD Disclosure

Cocrystal Pharma, Inc. (OTCBB:COCP) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Disclosure

Cocrystal Pharma, Inc. (the Company) will be presenting
information about the Companys antiviral therapies to investors
in connection with the 35th Annual J.P. Morgan Healthcare
Conference taking place in San Francisco, California from January
9-13, 2017. A copy of the presentation is included as an exhibit
to this report. In addition, the presentation materials may be
accessed on the Companys website,, by
selecting News, and then Presentations.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit No.
Presentation dated January 9, 2017

About Cocrystal Pharma, Inc. (OTCBB:COCP)

Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus. The polymerase inhibitors include both nucleosides (Nucs) and non-nucleosides. Its platform consists of computation, medicinal chemistry, click chemistry and X-ray crystallography. The Company determines the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide its design. The Company uses computational methods to screen and design product candidates using its cocrystal structural information.

Cocrystal Pharma, Inc. (OTCBB:COCP) Recent Trading Information

Cocrystal Pharma, Inc. (OTCBB:COCP) closed its last trading session 00.000 at 0.410 with 121,122 shares trading hands.

An ad to help with our costs